A Clinical Study Evaluating the Safety, Tolerability, and Effect on HIV Reservoir of Ibalizumab Combined With Chidamide (a Histone Deacetylase Inhibitor) in People Living With HIV
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
First Affiliated Hospital of Zhejiang University
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Subjects aged 18-65 years.
2. Confirmed HIV infection by both initial screening assay and Western blot (WB) confirmatory test.
3. Receiving a stable ART regimen for at least 6 months.
4. Viral load below the lower limit of detection.
5. CD4+ T-cell count \>200 cells/mm³.
6. Voluntarily signed the informed consent form and able to comply with regular follow-up visits, specimen collection, and monitoring/treatment of study-related adverse events.
7. Use effective contraception from 4 weeks prior to study initiation until 4 weeks after study completion.
You may not be if
1. Pregnant or breastfeeding women, or women planning to become pregnant during the study observation period.
2. Subjects with poor treatment adherence.
3. Receipt of immunosuppressants, other immunomodulatory agents, or cytotoxic drugs within 6 months prior to screening.
4. Presence of severe underlying cardiac, cerebral, hepatic, renal, or other systemic diseases; neutrophil count \<1000/mm³; platelet count \<75,000/mm³; allergy to the investigational drug; or other contraindications to treatment.
5. Presence of progressive (or active) malignancy, including but not limited to advanced, metastatic, or unresectable solid tumors or hematologic malignancies.
6. Unwillingness to sign the informed consent form.
Clareo Health | A Clinical Study Evaluating the Safety, Tolerability, and Effect on HIV Reservoir of Ibalizumab Combined With Chidamide (a Histone Deacetylase Inhibitor) in People Living With HIV
